<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01148979</url>
  </required_header>
  <id_info>
    <org_study_id>2010-P-000871</org_study_id>
    <nct_id>NCT01148979</nct_id>
  </id_info>
  <brief_title>Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.</brief_title>
  <official_title>Double-Blind, Placebo-Controlled, Randomized Trial of Adjunctive Lisdexamfetamine Dimesylate in Residual Symptoms of Major Depressive Disorder Partially Responsive to Selective Serotonin or Norepinephrine Reuptake Inhibitor Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mclean Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to test the effect of a newly-approved stimulant medication, lisdexamfetamine
      dimesylate (Vyvanse), on specific residual symptoms of depression found in some patients who
      are undergoing treatment with, but have only partially responded to, a selective-serotonin
      reuptake inhibitor (SSRI) or selective-norepinephrine reuptake inhibitor (SNRI)
      antidepressant. Specifically, the investigators hypothesize that symptoms potentially related
      to deficient dopaminergic activity, such as lassitude, apathy, reduced positive affect and
      impaired executive function, in particular, will improve. This protocol is designed to test
      the hypothesis that this cluster of co-occurring residual symptoms sometimes found in treated
      depression will respond as a group to adjunctive psychostimulant therapy. The investigators
      propose to demonstrate this cluster of residual depressive symptoms and to measure the effect
      of stimulant therapy on it. The investigators hope to better understand the specific symptoms
      in this clinical population that are likely to improve with stimulant therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol is designed to test the hypothesis that a cluster of co-occurring residual
      symptoms sometimes found in treated depression will respond as a group to psychostimulant
      therapy. This cluster includes apathy, reduced drive, fatigue, impaired executive function
      and other cognitive measures, and low positive affect. We propose to measure this cluster of
      symptoms in a population of residually depressed subjects demonstrating them, and then to
      measure the effect of stimulant therapy on this cluster, and each constituent symptom, as
      well as to measure its effect on subjects' overall functional impairment, and to document
      treatment emergent adverse effects. The goal is to gather data about the response of these
      residual symptoms to stimulant therapy. Since each subject will be exposed to active
      treatment and matched placebo, a benefit to individual participants will be to learn if their
      specific symptom burden is ameliorated by stimulant therapy, and what adverse effects may
      emerge for them. We hope to develop an understanding of the specific symptoms in this
      clinical population that are likely to improve with stimulant therapy. We also hope to be
      able to characterize the side effect burden of stimulant therapy in this clinical population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a double-blind, placebo-controlled, crossover study in which each subject will act as their own control after being randomly assigned to placebo or Lisdexamfetamine Dimesylate (Vyvanse) for the first 4 weeks of study treatment, then receiving the other for the second 4 weeks of treatment. The two 4-week treatment periods are separated by a washout of 2 weeks.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Both the study participant and the study investigators making evaluations are blinded to which treatment arm the participants are assigned to (i.e., whether they are receiving placebo or Vyvanse at any given point). Placebo and active medication capsules look identical.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Dysphoric Apathy/Retardation Sub-factor (MDAR) of Montgomery-Asberg Depression Rating Scale (MADRS) at 4 Weeks.</measure>
    <time_frame>Baseline to 4 weeks of treatment</time_frame>
    <description>The Montgomery-Asberg Depression Rating Scale Dysphoric Apathy Retardation subfactor (MDAR) is a 5-item subscale of the clinician-administered 10-item Montgomery-Asberg Depression Rating Scale (MADRS). MDAR score can range from 0-30 with a higher score representing a greater severity of depressive symptoms.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Adjunct Lisdexamfetamine (Vyvanse)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Lisdexamfetamine Dimesylate 20-50 mg capsule each morning for 4 weeks. After a washout period of 2 weeks, they receive Placebo capsule (matching Lisdexamfetamine Dimesylate (Vyvanse) capsule) each morning for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjunct Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive Placebo capsule (matching Lisdexamfetamine Dimesylate (Vyvanse) 20-50 mg capsule) each morning for 4 weeks. After a washout period of 2 weeks, they receive Lisdexamfetamine Dimesylate capsule each morning for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisdexamfetamine Dimesylate (Vyvanse)</intervention_name>
    <description>Lisdexamfetamine Dimesylate (Vyvanse) capsules dose ranging from 20mg to 50 mg.</description>
    <arm_group_label>Adjunct Lisdexamfetamine (Vyvanse)</arm_group_label>
    <other_name>Vyvanse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Lisdexamfetamine Dimesylate (Vyvanse)-matched placebo capsules.</description>
    <arm_group_label>Adjunct Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Meeting diagnostic criteria for major depression during the present episode of
             illness, currently with at least mild improvement by report (CGI-I ≥3) but with
             continuing residual symptoms.

          2. A score of ≥10 on MADRS items 1,2,6,7 and 8, (the MADRS Dysphoric Apathy/Retardation
             factor, Parker et al., 2003) at screening and randomization. These 5 items are:
             Apparent sadness, Reported sadness, Concentration difficulties, Lassitude, and
             Inability to feel. A score of ≥3 will be required for at least 2 of these items.

          3. A score of 3 or 4 on the Clinical Global Impression of Severity (CGI-S) at screening
             and randomization.

          4. At randomization subjects must have received therapeutic dosages of approved SSRI or
             SNRI agents for at least 8 weeks, with the last 4 weeks at a constant dosage.

          5. Females of Child-bearing Potential (FOCP) must have a negative serum beta Human
             Chorionic Gonadotropin (B-hCG) pregnancy test at the screening visit and a negative
             urine pregnancy test at the baseline visit, and agree to use one of the following
             methods of birth control: oral contraceptives, contraceptive implants, injectable
             contraceptives, IUDs, double-barrier contraception, sexual abstinence or vasectomized
             partner(s).

        Exclusion Criteria:

          1. Treatment within 4 weeks of randomization with any non-SSRI/SNRI antidepressant
             (trazodone is permitted up to 100 mg at night for sleep); any antipsychotic agent; any
             mood stabilizer; any standing benzodiazepine regimen other than at low doses for sleep
             (≤ 1 mg lorazepam HS or the equivalent); or a standing regimen of any other agent that
             may affect cognitive function (e.g., psychostimulants, including modafinil or
             R-modafinil).

          2. Any current or past psychotic disorder, Bipolar I or II disorder, Current panic
             disorder, History of ADHD, Antisocial Personality Disorder or Borderline Personality
             Disorder, Mental retardation or any dementing disorder.

          3. Covi Anxiety Scale score greater than Raskin Depression Scale score at Screening, to
             exclude subjects with more prominent anxiety than depression

          4. MADRS Sleep (item 4), or Appetite (item 5) &gt;3 at screening or randomization

          5. Initial insomnia at screening that is not adequately controlled by sleep medication
             (trazodone up to 100 mg HS for sleep and/or ≤ 1 mg lorazepam HS or the equivalent).

          6. Medical conditions that might be exacerbated by Vyvanse treatment, such as
             uncontrolled hypertension or angina; or conditions that would make study findings hard
             to interpret, such as hyperthyroidism

          7. History of seizure (other than infantile febrile seizures), any tic disorder, or a
             current diagnosis and/or family history of Tourette's Disorder.

          8. Known cardiac structural abnormality or any other condition that may affect cardiac
             performance

          9. Any clinically significant ECG or laboratory abnormality at Screening

         10. Current abnormal thyroid function, as defined by abnormal TSH at Screening (Treatment
             with a stable dose of thyroid medication for at least 3 months is permitted if TSH is
             normal at screening).

         11. Suicide attempt within the past 2 years or a history of any homicidal behavior.

         12. MADRS Suicidal thoughts (item 10) &gt;4 at any study visit, or if a patient is considered
             by the investigator to be at clinical risk of suicide at any time in the course of the
             study.

         13. resting sitting systolic blood pressure &gt;149mmHg or diastolic blood pressure &gt; 95mmHg.
             Subjects may be on monotherapy with anti-hypertensive medication.

         14. documented allergy, hypersensitivity, intolerance, or non-responsivity to
             methylphenidate or amphetamines.

         15. Subject has a history of a substance use disorder (abuse or dependence, as defined by
             DSM-IV-TR™), with the exception of nicotine dependence, within 6 months prior to
             screening.

         16. Subject has glaucoma

         17. Subject is taking other medications that have central nervous system (CNS) effects or
             affect performance, such as sedating antihistamines and decongestant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Alexander Bodkin Bodkin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bodkin JA, Lasser RA, Wines JD Jr, Gardner DM, Baldessarini RJ. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry. 1997 Apr;58(4):137-45.</citation>
    <PMID>9164423</PMID>
  </reference>
  <reference>
    <citation>Candy M, Jones L, Williams R, Tookman A, King M. Psychostimulants for depression. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006722. doi: 10.1002/14651858.CD006722.pub2. Review.</citation>
    <PMID>18425966</PMID>
  </reference>
  <reference>
    <citation>Dunkin JJ, Leuchter AF, Cook IA, Kasl-Godley JE, Abrams M, Rosenberg-Thompson S. Executive dysfunction predicts nonresponse to fluoxetine in major depression. J Affect Disord. 2000 Oct;60(1):13-23.</citation>
    <PMID>10940443</PMID>
  </reference>
  <reference>
    <citation>Edgar CJ, Pace-Schott EF, Wesnes KA. Approaches to measuring the effects of wake-promoting drugs: a focus on cognitive function. Hum Psychopharmacol. 2009 Jul;24(5):371-89. doi: 10.1002/hup.1034. Review.</citation>
    <PMID>19565524</PMID>
  </reference>
  <reference>
    <citation>Fava M, Graves LM, Benazzi F, Scalia MJ, Iosifescu DV, Alpert JE, Papakostas GI. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry. 2006 Nov;67(11):1754-9.</citation>
    <PMID>17196056</PMID>
  </reference>
  <reference>
    <citation>Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry. 2005 Jan;66(1):85-93.</citation>
    <PMID>15669893</PMID>
  </reference>
  <reference>
    <citation>Fleurence R, Williamson R, Jing Y, Kim E, Tran QV, Pikalov AS, Thase ME. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol Bull. 2009;42(3):57-90. Review.</citation>
    <PMID>19752841</PMID>
  </reference>
  <reference>
    <citation>Gorlyn M, Keilp JG, Grunebaum MF, Taylor BP, Oquendo MA, Bruder GE, Stewart JW, Zalsman G, Mann JJ. Neuropsychological characteristics as predictors of SSRI treatment response in depressed subjects. J Neural Transm (Vienna). 2008 Aug;115(8):1213-9. doi: 10.1007/s00702-008-0084-x. Epub 2008 Jul 16.</citation>
    <PMID>18629432</PMID>
  </reference>
  <reference>
    <citation>Parker RD, Flint EP, Bosworth HB, Pieper CF, Steffens DC. A three-factor analytic model of the MADRS in geriatric depression. Int J Geriatr Psychiatry. 2003 Jan;18(1):73-7.</citation>
    <PMID>12497559</PMID>
  </reference>
  <reference>
    <citation>Ravindran AV, Kennedy SH, O'Donovan MC, Fallu A, Camacho F, Binder CE. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2008 Jan;69(1):87-94.</citation>
    <PMID>18312042</PMID>
  </reference>
  <reference>
    <citation>Taylor BP, Bruder GE, Stewart JW, McGrath PJ, Halperin J, Ehrlichman H, Quitkin FM. Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients. Am J Psychiatry. 2006 Jan;163(1):73-8.</citation>
    <PMID>16390892</PMID>
  </reference>
  <reference>
    <citation>Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006 Jan;163(1):28-40.</citation>
    <PMID>16390886</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2010</study_first_submitted>
  <study_first_submitted_qc>June 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2010</study_first_posted>
  <results_first_submitted>March 8, 2017</results_first_submitted>
  <results_first_submitted_qc>April 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 23, 2017</results_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>J. Alexander Bodkin</investigator_full_name>
    <investigator_title>Director, Clinical Psychopharmacology Research Program</investigator_title>
  </responsible_party>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Cognitive Impairment</keyword>
  <keyword>Partial Response</keyword>
  <keyword>Residual Symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>35 potential subjects were screened for eligibility between September 2010 and April 2014 at McLean Hospital in Belmont, MA.</recruitment_details>
      <pre_assignment_details>Of the 35 subjects screened, 29 were randomized. Of the 6 not randomized, 3 did not meet inclusion criteria, 1 withdrew consent, and 2 were lost to follow post screening. Of the 29 randomized, 28 completed both parts of the study. One subject was lost to follow after 3 weeks in the first half. Data were analyzed for the 28 completers only.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo, Then Vyvanse</title>
          <description>Participants first received Placebo capsule (matching Lisdexamfetamine Dimesylate(Vyvanse) 20-50 mg capsule) each morning for 4 weeks. After a washout period of 2 weeks, they then received Lisdexamfetamine Dimesylate (Vyvanse) capsule each morning for 4 weeks, starting with initial dose 30 mg/d.
Lisdexamfetamine Dimesylate (Vyvanse): Lisdexamfetamine Dimesylate (Vyvanse) capsules dose ranging from 20mg to 50 mg.
Placebo: Lisdexamfetamine Dimesylate (Vyvanse)-matched placebo capsules.</description>
        </group>
        <group group_id="P2">
          <title>Vyvanse, Then Placebo</title>
          <description>Participants first received Lisdexamfetamine Dimesylate (Vyvanse) 20-50 mg capsule each morning for 4 weeks, staring with initial dose 30 mg/d. After a washout period of 2 weeks, they then received Placebo capsule (matching Lisdexamfetamine Dimesylate (Vyvanse) capsule) each morning for 4 weeks.
Lisdexamfetamine Dimesylate (Vyvanse): Lisdexamfetamine Dimesylate (Vyvanse) capsules dose ranging from 20mg to 50 mg.
Placebo: Lisdexamfetamine Dimesylate (Vyvanse)-matched placebo capsules.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo, Then Vyvanse</title>
          <description>Participants first received Placebo capsule (matching Lisdexamfetamine Dimesylate(Vyvanse) 20-50 mg capsule) each morning for 4 weeks. After a washout period of 2 weeks, they then received Lisdexamfetamine Dimesylate capsule each morning for 4 weeks.
Lisdexamfetamine Dimesylate (Vyvanse): Lisdexamfetamine Dimesylate (Vyvanse) capsules dose ranging from 20mg to 50 mg.
Placebo: Lisdexamfetamine Dimesylate (Vyvanse)-matched placebo capsules.</description>
        </group>
        <group group_id="B2">
          <title>Vyvanse, Then Placebo</title>
          <description>Participants first received Lisdexamfetamine Dimesylate 20-50 mg capsule each morning for 4 weeks. After a washout period of 2 weeks, they then received Placebo capsule (matching Lisdexamfetamine Dimesylate (Vyvanse) capsule) each morning for 4 weeks.
Lisdexamfetamine Dimesylate (Vyvanse): Lisdexamfetamine Dimesylate (Vyvanse) capsules dose ranging from 20mg to 50 mg.
Placebo: Lisdexamfetamine Dimesylate (Vyvanse)-matched placebo capsules.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.8" spread="10.6"/>
                    <measurement group_id="B2" value="48.9" spread="11.4"/>
                    <measurement group_id="B3" value="50.6" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Dysphoric Apathy/Retardation Sub-factor (MDAR) of Montgomery-Asberg Depression Rating Scale (MADRS) at 4 Weeks.</title>
        <description>The Montgomery-Asberg Depression Rating Scale Dysphoric Apathy Retardation subfactor (MDAR) is a 5-item subscale of the clinician-administered 10-item Montgomery-Asberg Depression Rating Scale (MADRS). MDAR score can range from 0-30 with a higher score representing a greater severity of depressive symptoms.</description>
        <time_frame>Baseline to 4 weeks of treatment</time_frame>
        <population>All participants who completed all 4 weeks on both treatments (i.e., Placebo and Vyvanse) were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Adjunct</title>
            <description>Participants first received Placebo capsule (matching Lisdexamfetamine Dimesylate(Vyvanse) 20-50 mg capsule) each morning for 4 weeks. After a washout period of 2 weeks, they then received Lisdexamfetamine Dimesylate (Vyvanse) capsule each morning for 4 weeks, starting with initial dose 30 mg/d.
Lisdexamfetamine Dimesylate (Vyvanse): Lisdexamfetamine Dimesylate (Vyvanse) capsules dose ranging from 20mg to 50 mg.
Placebo: Lisdexamfetamine Dimesylate (Vyvanse)-matched placebo capsules.</description>
          </group>
          <group group_id="O2">
            <title>Lisdexamfetamine Dimesylate (Vyvanse)</title>
            <description>Participants first received Lisdexamfetamine Dimesylate (Vyvanse) 20-50 mg capsule each morning for 4 weeks, staring with initial dose 30 mg/d. After a washout period of 2 weeks, they then received Placebo capsule (matching Lisdexamfetamine Dimesylate (Vyvanse) capsule) each morning for 4 weeks.
Lisdexamfetamine Dimesylate (Vyvanse): Lisdexamfetamine Dimesylate (Vyvanse) capsules dose ranging from 20mg to 50 mg.
Placebo: Lisdexamfetamine Dimesylate (Vyvanse)-matched placebo capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Dysphoric Apathy/Retardation Sub-factor (MDAR) of Montgomery-Asberg Depression Rating Scale (MADRS) at 4 Weeks.</title>
          <description>The Montgomery-Asberg Depression Rating Scale Dysphoric Apathy Retardation subfactor (MDAR) is a 5-item subscale of the clinician-administered 10-item Montgomery-Asberg Depression Rating Scale (MADRS). MDAR score can range from 0-30 with a higher score representing a greater severity of depressive symptoms.</description>
          <population>All participants who completed all 4 weeks on both treatments (i.e., Placebo and Vyvanse) were included in the analysis.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Mean MDAR score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.57" spread="3.98"/>
                    <measurement group_id="O2" value="13.46" spread="3.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Mean MDAR score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.08" spread="5.51"/>
                    <measurement group_id="O2" value="6.36" spread="5.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL in mean MDAR score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.49" spread="4.66"/>
                    <measurement group_id="O2" value="-7.08" spread="5.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis represents a within-subject comparison of change under treatment with Vyvanse versus change under treatment with placebo, using paired t-tests with each subject as their own control. All tests reported are two-tailed.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A Paired sample t-test was used to test the null hypothesis of no difference in MDAR score change after 4 weeks of treatment with Vyvanse versus placebo.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected over the 4 years of active subject participation.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adjunct Lisdexamfetamine (Vyvanse)</title>
          <description>Participants receive Lisdexamfetamine Dimesylate 20-50 mg capsule each morning for 4 weeks. After a washout period of 2 weeks, they receive Placebo capsule (matching Lisdexamfetamine Dimesylate (Vyvanse) capsule) each morning for 4 weeks.
Lisdexamfetamine Dimesylate (Vyvanse): Lisdexamfetamine Dimesylate (Vyvanse) capsules dose ranging from 20mg to 50 mg.</description>
        </group>
        <group group_id="E2">
          <title>Adjunct Placebo</title>
          <description>Participants receive Placebo capsule (matching Lisdexamfetamine Dimesylate (Vyvanse) 20-50 mg capsule) each morning for 4 weeks. After a washout period of 2 weeks, they receive Lisdexamfetamine Dimesylate capsule each morning for 4 weeks.
Placebo: Lisdexamfetamine Dimesylate (Vyvanse)-matched placebo capsules.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointesinal disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>diaphoresis</sub_title>
                <description>increased sweating</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>decreased libido</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>stomach virus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle tension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>irritability</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>increased activation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The small sample size and crossover design both weaken group differences.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>J. Alexander Bodkin, MD</name_or_title>
      <organization>McLean Hospital</organization>
      <phone>617-855-3186</phone>
      <email>abodkin@mclean.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

